US 12,005,079 B2
Biologically relevant orthogonal cytokine/receptor pairs
Kenan Christopher Garcia, Menlo Park, CA (US); Jonathan Sockolosky, San Francisco, CA (US); and Lora Picton, Foster City, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and University of Washington, Seattle, WA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and University of Washington, Seattle, WA (US)
Filed on Nov. 19, 2020, as Appl. No. 16/953,000.
Application 16/953,000 is a continuation of application No. 15/916,689, filed on Mar. 9, 2018, granted, now 10,869,887.
Application 15/916,689 is a continuation in part of application No. PCT/US2016/050511, filed on Sep. 7, 2016.
Claims priority of provisional application 62/375,089, filed on Aug. 15, 2016.
Claims priority of provisional application 62/217,364, filed on Sep. 11, 2015.
Prior Publication US 2021/0069243 A1, Mar. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); A61K 35/17 (2015.01); A61K 38/20 (2006.01); C07K 14/55 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); A61K 39/00 (2006.01)
CPC A61K 35/17 (2013.01) [A61K 38/1793 (2013.01); A61K 38/2013 (2013.01); C07K 14/55 (2013.01); C12N 5/0638 (2013.01); C12N 15/1034 (2013.01); A61K 2039/5156 (2013.01); A61K 2300/00 (2013.01); C12N 2740/10043 (2013.01)] 29 Claims
 
1. A nucleic acid encoding an engineered human IL-2 polypeptide, which comprises amino acid substitutions, numbered relative to reference SEQ ID NO:4:
E15S, E15T, E15Q, or E15H;
H16Q;
L19V or L19I;
D20T, D20S, D20L or D20M; and
M23L, M23S, M23V, M23A, or M23T;
and optionally comprises Q22K, Q22N, R81D, R81Y, T51I or a combination thereof.